Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 30, 2020HaemophiliaOpen Access

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

View Full Paper
Ask AI
Bookmark
Share

Authors

BNBeatrice NolanChildren's Health Ireland at CrumlinJMJohnny MahlanguNational Health Laboratory ServiceIPIngrid PabingerVascular Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nolan et al. (2020) studied this question.

synapsesocial.com/papers/69d91c827fca1f84ab6842dbhttps://doi.org/10.1111/hae.13953
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks2018 · 29 citations
  2. 2Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A2016 · 47 citations
  3. 3Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A2016 · 24 citations
  4. 4Clotting and chromogenic factor VIII assay variability in post‐infusion and spiked samples containing full‐length recombinant FVIII or recombinant factor VIII Fc fusion protein (<scp>rFVIIIF</scp>c)2018 · 18 citations
  5. 5Individualizing prophylaxis in hemophilia: a review2015 · 67 citations